Figure 3. Kaplan–Meier Analyses (A and B) and Hazard Ratios (C and D) of 24 W-cCDP Grouped by OCR Exposure Quartiles vs Overall Control, and Hazard Ratios of 24 W-cCDP, T25FW, and 9HPT (E and F) by High (Quartiles 3/4) vs Low (Quartiles 1/2) OCR Exposure in Patients With RMS^a (A, C, E) or PPMS^b (B, D, F).

Hazard ratios were estimated by a stratified Cox regression model with treatment group as a covariate. ^a,bStratified by region (the United States vs ROW), ^abaseline EDSS (<4.0 vs ≥4.0), and ^bage (≤45 vs >45 years). Treated patients with missing C_mean values were excluded. 9HPT = Nine-Hole Peg Test; 24 W-cCDP = 24-week composite confirmed disease progression; C_mean = average OCR serum concentration in an individual patient over their treatment period; EDSS = Expanded Disability Status Scale; IFN = interferon; OCR = ocrelizumab; PBO = placebo; PPMS = primary progressive MS; Q = quartile; RMS = relapsing MS; ROW = rest of world; T25FW = Timed 25-Foot Walk.